Skip to main content Accessibility help

We use cookies to distinguish you from other users and to provide you with a better experience on our websites. Close this message to accept cookies or find out how to manage your cookie settings.

Close cookie message
×
Hostname: page-component-8448b6f56d-qsmjn Total loading time: 0 Render date: 2024-04-23T11:31:25.738Z Has data issue: false hasContentIssue false

Chapter 9 - Restless legs syndrome

Published online by Cambridge University Press:  05 July 2015

By
Roongroj Bhidayasiri  and
Pattamon Panyakaew
Edited by
Joseph H. Friedman
Joseph H. Friedman
Affiliation:
Department of Neurology, Brown University
Get access

Summary

A summary is not available for this content so a preview has been provided. Please use the Get access link above for information on how to access this content.
Image of the first page of this content. For PDF version, please use the ‘Save PDF’ preceeding this image.'
Type
Chapter
Information
Medication-Induced Movement Disorders , pp. 91 - 103
Publisher: Cambridge University Press
Print publication year: 2015

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Allen, RP, Picchietti, D, Hening, WA, Trenkwalder, C, Walters, AS, Montplaisi, J. Restless legs syndrome: diagnostic criteria, special considerations, and epidemiology. A report from the restless legs syndrome diagnosis and epidemiology workshop at the National Institutes of Health. Sleep Med. 2003 Mar;4(2):101–19. PubMed PMID: 14592341.CrossRefGoogle ScholarPubMed
American Academy of Sleep Medicine. International classification of sleep disorders. 2nd ed. Westchester, IL.: American Academy of Sleep Medicine; 2005.Google Scholar
Allen, RP, Walters, AS, Montplaisir, J, Hening, W, Myers, A, Bell, TJ, et al. Restless legs syndrome prevalence and impact: REST general population study. Arch Intern Med. 2005 Jun 13;165(11):1286–92. PubMed PMID: 15956009.CrossRefGoogle ScholarPubMed
Allen, RP, Bharmal, M, Calloway, M. Prevalence and disease burden of primary restless legs syndrome: results of a general population survey in the United States. Mov Disord. 2011 Jan;26(1):114–20. PubMed PMID: 21322022.CrossRefGoogle ScholarPubMed
Chokroverty, S. Introduction: Comorbid disorders and special populations. In: Hening, W, Allen, RP, Chokroverty, S, Earley, CJ, editors. Restless legs syndrome. Philadelphia: Saunders, Elsevier; 2009. p. 161–6.Google Scholar
Ekbom, KA. Restless legs syndrome. Neurology. 1960 Sep;10:868–73. PubMed PMID: 13726241.CrossRefGoogle ScholarPubMed
Morgan, LK. Letter: Restless legs: precipitated by beta blockers, relieved by orphenadrine. Med J Aust. 1975 Nov 8;2(19):753. PubMed PMID: 1214686.Google ScholarPubMed
Lutz, EG. Restless legs, anxiety and caffeinism. J Clin Psychiatry. 1978 Sep;39(9):693–8. PubMed PMID: 690085.Google ScholarPubMed
Ginsberg, HN. Propranolol in the treatment of restless legs syndrome induced by imipramine withdrawal. Am J Psychiatry. 1986 Jul;143(7):938. PubMed PMID: 3717447.Google ScholarPubMed
Derom, E, Elinck, W, Buylaert, W, van der Straeten, M. Which beta–blocker for the restless leg? Lancet. 1984 Apr 14;1(8381):857. PubMed PMID: 6143173.CrossRefGoogle ScholarPubMed
Hoque, R, Chesson, AL Jr. Pharmacologically induced/exacerbated restless legs syndrome, periodic limb movements of sleep, and REM behavior disorder/REM sleep without atonia: literature review, qualitative scoring, and comparative analysis. J Clin Sleep Med. 2010 Feb 15;6(1):79–83. PubMed PMID: 20191944. Pubmed Central PMCID: 2823282.CrossRefGoogle ScholarPubMed
Trenkwalder, C, Paulus, W. Restless legs syndrome: pathophysiology, clinical presentation and management. Nat Rev Neurol. 2010 Jun;6(6):337–46. PubMed PMID: 20531433.CrossRefGoogle ScholarPubMed
Salminen, AV, Rimpila, V, Polo, O. Peripheral hypoxia in restless legs syndrome (Willis–Ekbom disease). Neurology. 2014 Apr 30. PubMed PMID: 24789861.CrossRefGoogle Scholar
Rios Romenets, S, Dauvilliers, Y, Cochen De Cock, V, Carlander, B, Bayard, S, Galatas, C, et al. Restless legs syndrome outside the blood–brain barrier–exacerbation by domperidone in Parkinson’s disease. Parkinsonism Relat Disord. 2013 Jan;19(1):92–4. PubMed PMID: 22922159.CrossRefGoogle ScholarPubMed
Blier, P, El Mansari, M. Serotonin and beyond: therapeutics for major depression. Philos Trans R Soc Lond B Biol Sci. 2013;368(1615):20120536. PubMed PMID: 23440470. Pubmed Central PMCID: 3638389.CrossRefGoogle ScholarPubMed
Perez–Lloret, S, Rey, MV, Bondon–Guitton, E, Rascol, O, Montastruc, AJ, French Association of Regional Pharmacovigilance C. Drugs associated with restless legs syndrome: a case/noncase study in the French Pharmacovigilance Database. J Clin Psychopharmacol. 2012 Dec;32(6):824–7. PubMed PMID: 23131889.CrossRefGoogle Scholar
Allen, RP, Earley, CJ. Augmentation of the restless legs syndrome with carbidopa/levodopa. Sleep. 1996 Apr;19(3):205–13. PubMed PMID: 8723377.CrossRefGoogle ScholarPubMed
Stahl, SM. Antidepressants. In: Stahl, SM, editor. Stahl’s essential psychopharmacology: Neuroscientific basis and practical applications. New York: Cambridge University Press; 2008. p. 511–666.Google Scholar
Sanz–Fuentenebro, FJ, Huidobro, A, Tejadas–Rivas, A. Restless legs syndrome and paroxetine. Acta Psychiatr Scand. 1996 Dec;94(6):482–4. PubMed PMID: 9021005.CrossRefGoogle ScholarPubMed
Page, RL, 2nd, Ruscin, JM, Bainbridge, JL, Brieke, AA. Restless legs syndrome induced by escitalopram: case report and review of the literature. Pharmacotherapy. 2008 Feb;28(2):271–80. PubMed PMID: 18225972.CrossRefGoogle ScholarPubMed
Chou, KJ, Chen, PY, Huang, MC. Restless legs syndrome following the combined use of quetiapine and paroxetine. Prog Neuropsychopharmacol Biol Psychiatry. 2010 Aug 16;34(6):1139–40. PubMed PMID: 20470847.CrossRefGoogle ScholarPubMed
Buskova, J, Vorlova, T, Pisko, J, Sonka, K. Severe sleep-related movement disorder induced by sertraline. Sleep Med. 2012 Jun;13(6):769–70. PubMed PMID: 22440086.CrossRefGoogle ScholarPubMed
Belli, H, Akbudak, M, Ural, C. Duloxetine-related galactorrhea and restless legs syndrome: a case report. Psychiatr Danub. 2013 Sep;25(3):266–7. PubMed PMID: 24048395.Google ScholarPubMed
Perroud, N, Lazignac, C, Baleydier, B, Cicotti, A, Maris, S, Damsa, C. Restless legs syndrome induced by citalopram: a psychiatric emergency? Gen Hosp Psychiatry. 2007 Jan-Feb;29(1):72–4. PubMed PMID: 17189751.CrossRefGoogle ScholarPubMed
Ozturk, O, Eraslan, D, Kumral, E. Oxcarbazepine treatment for paroxetine-induced restless leg syndrome. Gen Hosp Psychiatry. 2006 May-Jun;28(3):264–5. PubMed PMID: 16675374.CrossRefGoogle ScholarPubMed
Chang, CC, Shiah, IS, Chang, HA, Mao, WC. Does domperidone potentiate mirtazapine-associated restless legs syndrome? Prog Neuropsychopharmacol Biol Psychiatry. 2006 Mar;30(2):316–8. PubMed PMID: 16309808.CrossRefGoogle ScholarPubMed
Prospero-Garcia, KA, Torres-Ruiz, A, Ramirez-Bermudez, J, Velazquez-Moctezuma, J, Arana-Lechuga, Y, Teran-Perez, G. Fluoxetine-mirtazapine interaction may induce restless legs syndrome: report of 3 cases from a clinical trial. J Clin Psychiatry. 2006 Nov;67(11):1820. PubMed PMID: 17196069.CrossRefGoogle ScholarPubMed
Agargun, MY, Kara, H, Ozbek, H, Tombul, T, Ozer, OA. Restless legs syndrome induced by mirtazapine. J Clin Psychiatry. 2002 Dec;63(12):1179. PubMed PMID: 12530413.CrossRefGoogle ScholarPubMed
Hargrave, R, Beckley, DJ. Restless leg syndrome exacerbated by sertraline. Psychosomatics. 1998 Mar-Apr;39(2):177–8. PubMed PMID: 9584547.CrossRefGoogle ScholarPubMed
Bahk, WM, Pae, CU, Chae, JH, Jun, TY, Kim, KS. Mirtazapine may have the propensity for developing a restless legs syndrome? A case report. Psychiatry Clin Neurosci. 2002 Apr;56(2):209–10. PubMed PMID: 11952928.CrossRefGoogle ScholarPubMed
Bonin, B, Vandel, P, Kantelip, JP. Mirtazapine and restless leg syndrome: a case report. Therapie. 2000 Sep-Oct;55(5):655–6. PubMed PMID: 11201984.Google ScholarPubMed
Pae, CU, Kim, TS, Kim, JJ, Chae, JH, Lee, CU, Lee, SJ, et al. Re-administration of mirtazapine could overcome previous mirtazapine-associated restless legs syndrome? Psychiatry Clin Neurosci. 2004 Dec;58(6):669–70. PubMed PMID: 15601394.CrossRefGoogle ScholarPubMed
Kim, SW, Shin, IS, Kim, JM, Park, KH, Youn, T, Yoon, JS. Factors potentiating the risk of mirtazapine-associated restless legs syndrome. Hum Psychopharmacol. 2008 Oct;23(7):615–20. PubMed PMID: 18756499.CrossRefGoogle ScholarPubMed
Brown, LK, Dedrick, DL, Doggett, JW, Guido, PS. Antidepressant medication use and restless legs syndrome in patients presenting with insomnia. Sleep Med. 2005 Sep;6(5):443–50. PubMed PMID: 16084763.CrossRefGoogle ScholarPubMed
Dimmitt, SB, Riley, GJ. Selective serotonin receptor uptake inhibitors can reduce restless legs symptoms. Arch Intern Med. 2000 Mar 13;160(5):712. PubMed PMID: 10724062.CrossRefGoogle ScholarPubMed
Leutgeb, U, Martus, P. Regular intake of non-opioid analgesics is associated with an increased risk of restless legs syndrome in patients maintained on antidepressants. Eur J Med Res. 2002 Aug 30;7(8):368–78. PubMed PMID: 12204845.Google ScholarPubMed
Berger, K. Non-opioid analgesics and the risk of restless leg syndrome-a spurious association? Sleep Med. 2003 Jul;4(4):351–2. PubMed PMID: 14592311.CrossRefGoogle ScholarPubMed
Ohayon, MM, Roth, T. Prevalence of restless legs syndrome and periodic limb movement disorder in the general population. J Psychosom Res. 2002 Jul;53(1):547–54. PubMed PMID: 12127170.CrossRefGoogle ScholarPubMed
Rottach, KG, Schaner, BM, Kirch, MH, Zivotofsky, AZ, Teufel, LM, Gallwitz, T, et al. Restless legs syndrome as side effect of second generation antidepressants. J Psychiatr Res. 2008 Nov;43(1):70–5. PubMed PMID: 18468624.CrossRefGoogle ScholarPubMed
Winkelmann, J, Prager, M, Lieb, R, Pfister, H, Spiegel, B, Wittchen, HU, et al. “Anxietas tibiarum”. Depression and anxiety disorders in patients with restless legs syndrome. J Neurol. 2005 Jan;252(1):67–71. PubMed PMID: 15654556.CrossRefGoogle ScholarPubMed
Picchietti, D, Winkelman, JW. Restless legs syndrome, periodic limb movements in sleep, and depression. Sleep. 2005 Jul;28(7):891–8. PubMed PMID: 16124671.Google ScholarPubMed
Bayard, M, Bailey, B, Acharya, D, Ambreen, F, Duggal, S, Kaur, T, et al. Bupropion and restless legs syndrome: a randomized controlled trial. J Am Board Fam Med. 2011 Jul-Aug;24(4):422–8. PubMed PMID: 21737767.CrossRefGoogle ScholarPubMed
Goldstein, JM. The new generation of antipsychotic drugs: how atypical are they? Int J Neuropsychopharmacol. 2000 Dec;3(4):339–49. PubMed PMID: 11343614.CrossRefGoogle Scholar
Kang, SG, Park, YM, Choi, JE, Lim, SW, Lee, HJ, Lee, SH, et al. Association study between antipsychotic-induced restless legs syndrome and polymorphisms of monoamine oxidase genes in schizophrenia. Hum Psychopharmacol. 2010 Jul;25(5):397–403. PubMed PMID: 20589923.CrossRefGoogle ScholarPubMed
Horiguchi, J, Yamashita, H, Mizuno, S, Kuramoto, Y, Kagaya, A, Yamawaki, S, et al. Nocturnal eating/drinking syndrome and neuroleptic-induced restless legs syndrome. Int Clin Psychopharmacol. 1999 Jan;14(1):33–6. PubMed PMID: 10221640. Epub 1999/04/30. eng.Google ScholarPubMed
Terao, T, Yoshimura, R, Terao, M, Yasumatsu, S, Ohmori, O, Shiratsuchi, T, et al. Restless legs syndrome induced by psychotropics. Ann Clin Psychiatry. 1992;4(2):127–30.CrossRefGoogle Scholar
Akpinar, S. Treatment of restless legs syndrome with levodopa plus benserazide. Arch Neurol. 1982 Nov;39(11):739. PubMed PMID: 7126008.CrossRefGoogle ScholarPubMed
Duggal, HS, Mendhekar, DN. Clozapine-associated restless legs syndrome. J Clin Psychopharmacol. 2007 Feb;27(1):89–90. PubMed PMID: 17224721. Epub 2007/01/17. eng.CrossRefGoogle ScholarPubMed
Kraus, T, Schuld, A, Pollmacher, T. Periodic leg movements in sleep and restless legs syndrome probably caused by olanzapine. J Clin Psychopharmacol. 1999 Oct;19(5):478–9. PubMed PMID: 10505594. Epub 1999/10/03. eng.CrossRefGoogle ScholarPubMed
Wetter, TC, Brunner, J, Bronisch, T. Restless legs syndrome probably induced by risperidone treatment. Pharmacopsychiatry. 2002 May;35(3):109–11. PubMed PMID: 12107855. Epub 2002/07/11. eng.CrossRefGoogle ScholarPubMed
Pinninti, NR, Mago, R, Townsend, J, Doghramji, K. Periodic restless legs syndrome associated with quetiapine use: a case report. J Clin Psychopharmacol. 2005 Dec;25(6):617–8. PubMed PMID: 16282854. Epub 2005/11/12. eng.CrossRefGoogle ScholarPubMed
Urbano, MR, Ware, JC. Restless legs syndrome caused by quetiapine successfully treated with ropinirole in 2 patients with bipolar disorder. J Clin Psychopharmacol. 2008 Dec;28(6):704–5. PubMed PMID: 19011442. Epub 2008/11/18. eng.CrossRefGoogle ScholarPubMed
Kang, SG, Lee, HJ, Kim, L. Restless legs syndrome and periodic limb movements during sleep probably associated with olanzapine. J Psychopharmacol. 2009 Jul;23(5):597–601. PubMed PMID: 18562412. Epub 2008/06/20. eng.CrossRefGoogle ScholarPubMed
Khalid, I, Rana, L, Khalid, TJ, Roehrs, T. Refractory restless legs syndrome likely caused by olanzapine. J Clin Sleep Med. 2009 Feb 15;5(1):68–9. PubMed PMID: 19317385. Pubmed Central PMCID: 2637170. Epub 2009/03/26. eng.CrossRefGoogle ScholarPubMed
Rittmannsberger, H, Werl, R. Restless legs syndrome induced by quetiapine: report of seven cases and review of the literature. Int J Neuropsychopharmacol. 2013 Jul;16(6):1427–31. PubMed PMID: 23331473.CrossRefGoogle ScholarPubMed
Bolanos-Vergaray, J, Obaya, JC, Gonzalez, R, Echeverri, C, Piquer, P. Restless legs syndrome due to aripiprazole. Eur J Clin Pharmacol. 2011 May;67(5):539–40. PubMed PMID: 21104073.CrossRefGoogle ScholarPubMed
Webb, J. Co-occurring akathisia and restless legs syndrome likely induced by quetiapine. J Neuropsychiatry Clin Neurosci. 2012 Spring;24(2):E46–7. PubMed PMID: 22772702.Google ScholarPubMed
Raveendranathan, D, Shiva, L, Venkatasubramanian, G, Rao, MG, Varambally, S, Gangadhar, BN. Clozapine-induced restless legs syndrome treated with aripiprazole. J Neuropsychiatry Clin Neurosci. 2013 Spring;25(2):E62–3. PubMed PMID: 23686071.CrossRefGoogle ScholarPubMed
Aggarwal, S, Dodd, S, Berk, M. Restless leg syndrome associated with olanzapine: a case series. Curr Drug Saf. 2010 Apr;5(2):129–31. PubMed PMID: 20406161.CrossRefGoogle ScholarPubMed
Kang, SG, Lee, HJ, Jung, SW, Cho, SN, Han, C, Kim, YK, et al. Characteristics and clinical correlates of restless legs syndrome in schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry. 2007 Jun 30;31(5):1078–83. PubMed PMID: 17459547.CrossRefGoogle ScholarPubMed
Jagota, P, Asawavichienjinda, T, Bhidayasiri, R. Prevalence of neuroleptic-induced restless legs syndrome in patients taking neuroleptic drugs. J Neurol Sci. 2012 Mar 15; 314 (1–2): 158–60. PubMed PMID: 22099638.CrossRefGoogle ScholarPubMed
Kang, SG, Lee, HJ, Choi, JE, Park, YM, Park, JH, Han, C, et al. Association study between antipsychotics-induced restless legs syndrome and polymorphisms of dopamine D1, D2, D3, and D4 receptor genes in schizophrenia. Neuropsychobiology. 2008; 57 (1–2): 49–54. PubMed PMID: 18451638.CrossRefGoogle ScholarPubMed
Desautels, A, Turecki, G, Montplaisir, J, Brisebois, K, Sequeira, A, Adam, B, et al. Evidence for a genetic association between monoamine oxidase A and restless legs syndrome. Neurology. 2002 Jul 23;59(2):215–9. PubMed PMID: 12136060.CrossRefGoogle ScholarPubMed
Winkelmann, J, Schadrack, J, Wetter, TC, Zieglgansberger, W, Trenkwalder, C. Opioid and dopamine antagonist drug challenges in untreated restless legs syndrome patients. Sleep Med. 2001 Jan;2(1):57–61. PubMed PMID: 11152983.CrossRefGoogle ScholarPubMed
Drotts, DL, Vinson, DR. Prochlorperazine induces akathisia in emergency patients. Ann Emerg Med. 1999 Oct; 34 (4 Pt 1): 469–75. PubMed PMID: 10499947.CrossRefGoogle ScholarPubMed
Parlak, I, Atilla, R, Cicek, M, Parlak, M, Erdur, B, Guryay, M, et al. Rate of metoclopramide infusion affects the severity and incidence of akathisia. Emerg Medicine J. 2005 Sep;22(9):621–4. PubMed PMID: 16113179. Pubmed Central PMCID: 1726928.CrossRefGoogle ScholarPubMed
Erro, R, Amboni, M, Allocca, R, Santangelo, G, Barone, P, Vitale, C. Hemi-restless legs syndrome induced by clebopride. Eur J Neurol. 2012 Jun;19(6):e59. PubMed PMID: 22577755.CrossRefGoogle ScholarPubMed
Tosini, G, Dirden, JC. Dopamine inhibits melatonin release in the mammalian retina: in vitro evidence. Neurosci Lett. 2000 Jun 2;286(2):119–22. PubMed PMID: 10825651.CrossRefGoogle ScholarPubMed
Lewy, AJ, Wehr, TA, Goodwin, FK, Newsome, DA, Markey, SP. Light suppresses melatonin secretion in humans. Science. 1980 Dec 12;210(4475):1267–9. PubMed PMID: 7434030.CrossRefGoogle ScholarPubMed
Whittom, S, Dumont, M, Petit, D, Desautels, A, Adam, B, Lavigne, G, et al. Effects of melatonin and bright light administration on motor and sensory symptoms of RLS. Sleep Med. 2010 Apr;11(4):351–5. PubMed PMID: 20226733.CrossRefGoogle Scholar
Drake, ME. Restless legs with antiepileptic drug therapy. Clin Neurol Neurosurg. 1988;90(2):151–4. PubMed PMID: 3145164.CrossRefGoogle ScholarPubMed
Chen, JT, Garcia, PA, Alldredge, BK. Zonisamide-induced restless legs syndrome. Neurology. 2003 Jan 14;60(1):147. PubMed PMID: 12525743.CrossRefGoogle ScholarPubMed
Velasco, PE, Goiburu, JA, Pinel, RS. Restless legs syndrome induced by zonisamide. Mov Disord. 2007 Jul 30;22(10):1517–8. PubMed PMID: 17486608.CrossRefGoogle ScholarPubMed
Romigi, A, Izzi, F, Placidi, F, Sperli, F, Cervellino, A, Marciani, MG. Topiramate-induced restless legs syndrome: a report of two cases. J Neurol. 2007 Aug;254(8):1120–1. PubMed PMID: 17473947.CrossRefGoogle ScholarPubMed
Bermejo, PE. Restless legs syndrome induced by topiramate: two more cases. J Neurol. 2009 Apr;256(4):662–3. PubMed PMID: 19444538.CrossRefGoogle ScholarPubMed
Okada, M, Kaneko, S, Hirano, T, Mizuno, K, Kondo, T, Otani, K, et al. Effects of zonisamide on dopaminergic system. Epilepsy Res. 1995 Nov;22(3):193–205. PubMed PMID: 8991786.CrossRefGoogle ScholarPubMed
Silverdale, MA, Nicholson, SL, Crossman, AR, Brotchie, JM. Topiramate reduces levodopa-induced dyskinesia in the MPTP-lesioned marmoset model of Parkinson’s disease. Mov Disord. 2005 Apr;20(4):403–9. PubMed PMID: 15593312.CrossRefGoogle ScholarPubMed
Johnson, BA. Topiramate-induced neuromodulation of cortico-mesolimbic dopamine function: a new vista for the treatment of comorbid alcohol and nicotine dependence? Addict Behav. 2004 Sep;29(7):1465–79. PubMed PMID: 15345276.CrossRefGoogle ScholarPubMed
Garcia-Borreguero, D, Ferini-Strambi, L, Kohnen, R, O’Keeffe, S, Trenkwalder, C, Hogl, B, et al. European guidelines on management of restless legs syndrome: report of a joint task force by the European Federation of Neurological Societies, the European Neurological Society and the European Sleep Research Society. Eur J Neurol. 2012 Nov;19(11):1385–96. PubMed PMID: 22937989.CrossRefGoogle ScholarPubMed
Trenkwalder, C, Hening, WA, Montagna, P, Oertel, WH, Allen, RP, Walters, AS, et al. Treatment of restless legs syndrome: an evidence-based review and implications for clinical practice. Mov Disord. 2008 Dec 15;23(16):2267–302. PubMed PMID: 18925578.CrossRefGoogle ScholarPubMed
Trenkwalder, C, Benes, H, Grote, L, Garcia-Borreguero, D, Hogl, B, Hopp, M, et al. Prolonged release oxycodone-naloxone for treatment of severe restless legs syndrome after failure of previous treatment: a double-blind, randomised, placebo-controlled trial with an open-label extension. Lancet Neurol. 2013 Dec;12(12):1141–50. PubMed PMID: 24140442.CrossRefGoogle ScholarPubMed
Vetrugno, R, La Morgia, C, D’Angelo, R, Loi, D, Provini, F, Plazzi, G, et al. Augmentation of restless legs syndrome with long-term tramadol treatment. Mov Disord. 2007 Feb 15;22(3):424–7. PubMed PMID: 17230457.CrossRefGoogle ScholarPubMed
Earley, CJ, Allen, RP. Restless legs syndrome augmentation associated with tramadol. Sleep Med. 2006 Oct;7(7):592–3. PubMed PMID: 16926116.CrossRefGoogle ScholarPubMed
Garcia-Borreguero, D, Kohnen, R, Silber, MH, Winkelman, JW, Earley, CJ, Hogl, B, et al. The long-term treatment of restless legs syndrome/Willis-Ekbom disease: evidence-based guidelines and clinical consensus best practice guidance: a report from the International Restless Legs Syndrome Study Group. Sleep Med. 2013 Jul;14(7):675–84. PubMed PMID: 23859128.CrossRefGoogle ScholarPubMed
Terao, T, Terao, M, Yoshimura, R, Abe, K. Restless legs syndrome induced by lithium. Biol Psychiatry. 1991 Dec 1;30(11):1167–70. PubMed PMID: 1777530.CrossRefGoogle ScholarPubMed
Heiman, EM, Christie, M. Lithium-aggravated nocturnal myoclonus and restless legs syndrome. Am J Psychiatry. 1986 Sep;143(9):1191–2. PubMed PMID: 3752305.Google ScholarPubMed
LaRochelle, JS, Karp, BI. Restless legs syndrome due to interferon-alpha. Mov Disord. 2004 Jun;19(6):730–1. PubMed PMID: 15197722.CrossRefGoogle ScholarPubMed
Inal, S, Golbas, C, Onec, K, Okyay, GU, Derici, UB. Methoxy polyethylene glycol-epoetin beta (CERA) induced restless legs syndrome. Ther Apher Dial. 2012 Aug;16(4):378–9. PubMed PMID: 22817128.CrossRefGoogle ScholarPubMed
Tan, EK, Ho, SC, Koh, L, Pavanni, R. An urge to move with L-thyroxine: clinical, biochemical, and polysomnographic correlation. Mov Disord. 2004 Nov;19(11):1365–7. PubMed PMID: 15378680.CrossRefGoogle ScholarPubMed
Santamaria, J, Iranzo, A, Tolosa, E. Development of restless legs syndrome after dopaminergic treatment in a patient with periodic leg movements in sleep. Sleep Med. 2003 Mar;4(2):153–5. PubMed PMID: 14592347.CrossRefGoogle Scholar
Garcia-Borreguero, D, Williams, AM. Dopaminergic augmentation of restless legs syndrome. Sleep Medicine Rev. 2010 Oct;14(5):339–46. PubMed PMID: 20219397.CrossRefGoogle ScholarPubMed
Garcia-Borreguero, D, Hogl, B, Ferini-Strambi, L, Winkelman, J, Hill-Zabala, C, Asgharian, A, et al. Systematic evaluation of augmentation during treatment with ropinirole in restless legs syndrome (Willis-Ekbom disease): results from a prospective, multicenter study over 66 weeks. Mov Disord. 2012 Feb;27(2):277–83. PubMed PMID: 22328464.CrossRefGoogle ScholarPubMed
Allen, RP, Ondo, WG, Ball, E, Calloway, MO, Manjunath, R, Higbie, RL, et al. Restless legs syndrome (RLS) augmentation associated with dopamine agonist and levodopa usage in a community sample. Sleep Med. 2011 May;12(5):431–9. PubMed PMID: 21493132.CrossRefGoogle Scholar
Chokroverty, S. Long-term management issues in restless legs syndrome. Mov Disord. 2011 Jul;26(8):1378–85. PubMed PMID: 21538518.CrossRefGoogle ScholarPubMed
Winkelman, JW, Johnston, L. Augmentation and tolerance with long-term pramipexole treatment of restless legs syndrome (RLS). Sleep Med. 2004 Jan;5(1):9–14. PubMed PMID: 14725821.CrossRefGoogle ScholarPubMed
Benes, H, Heinrich, CR, Ueberall, MA, Kohnen, R. Long-term safety and efficacy of cabergoline for the treatment of idiopathic restless legs syndrome: results from an open-label 6-month clinical trial. Sleep. 2004 Jun 15;27(4):674–82. PubMed PMID: 15283002.CrossRefGoogle ScholarPubMed
Trenkwalder, C, Benes, H, Grote, L, Happe, S, Hogl, B, Mathis, J, et al. Cabergoline compared to levodopa in the treatment of patients with severe restless legs syndrome: results from a multi-center, randomized, active controlled trial. Mov Disord. 2007 Apr 15;22(5):696–703. PubMed PMID: 17274039.CrossRefGoogle ScholarPubMed
Benes, H, Garcia-Borreguero, D, Ferini-Strambi, L, Schollmayer, E, Fichtner, A, Kohnen, R. Augmentation in the treatment of restless legs syndrome with transdermal rotigotine. Sleep Med. 2012 Jun;13(6):589–97. PubMed PMID: 22503658.CrossRefGoogle ScholarPubMed
Hogl, B, Garcia-Borreguero, D, Kohnen, R, Ferini-Strambi, L, Hadjigeorgiou, G, Hornyak, M, et al. Progressive development of augmentation during long-term treatment with levodopa in restless legs syndrome: results of a prospective multi-center study. J Neurol. 2010 Feb;257(2):230–7. PubMed PMID: 19756826. Pubmed Central PMCID: 3085743.CrossRefGoogle ScholarPubMed
Ondo, W, Romanyshyn, J, Vuong, KD, Lai, D. Long-term treatment of restless legs syndrome with dopamine agonists. Arch Neurol. 2004 Sep;61(9):1393–7. PubMed PMID: 15364685.CrossRefGoogle ScholarPubMed
Garcia-Borreguero, D, Allen, RP, Kohnen, R, Hogl, B, Trenkwalder, C, Oertel, W, et al. Diagnostic standards for dopaminergic augmentation of restless legs syndrome: report from a World Association of Sleep Medicine-International Restless Legs Syndrome Study Group consensus conference at the Max Planck Institute. Sleep Med. 2007 Aug;8(5):520–30. PubMed PMID: 17544323.Google Scholar
Guilleminault, C, Cetel, M, Philip, P. Dopaminergic treatment of restless legs and rebound phenomenon. Neurology. 1993 Feb;43(2):445. PubMed PMID: 8094897.CrossRefGoogle ScholarPubMed
Walters, AS, Hening, W, Rubinstein, M, Chokroverty, S. A clinical and polysomnographic comparison of neuroleptic-induced akathisia and the idiopathic restless legs syndrome. Sleep. 1991 Aug;14(4):339–45. PubMed PMID: 1682986. Epub 1991/08/01. eng.Google ScholarPubMed
Paulus, W, Trenkwalder, C. Less is more: pathophysiology of dopaminergic-therapy-related augmentation in restless legs syndrome. Lancet Neurol. 2006 Oct;5(10):878–86. PubMed PMID: 16987735.CrossRefGoogle ScholarPubMed

Save book to Kindle

To save this book to your Kindle, first ensure coreplatform@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

Available formats
×

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

Available formats
×

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

Available formats
×